- Home
- OSW vs MIRM Comparison
OSW vs MIRM Comparison
Compare OSW & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSW
- MIRM
- Stock Information
- Founded
- OSW 2017
- MIRM 2018
- Country
- OSW Bahamas
- MIRM United States
- Employees
- OSW N/A
- MIRM N/A
- Industry
- OSW Hotels/Resorts
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- OSW Consumer Discretionary
- MIRM Health Care
- Exchange
- OSW Nasdaq
- MIRM Nasdaq
- Market Cap
- OSW 1.7B
- MIRM 1.9B
- IPO Year
- OSW N/A
- MIRM 2019
- Fundamental
- Price
- OSW $16.94
- MIRM $39.10
- Analyst Decision
- OSW Strong Buy
- MIRM Strong Buy
- Analyst Count
- OSW 4
- MIRM 11
- Target Price
- OSW $19.75
- MIRM $58.55
- AVG Volume (30 Days)
- OSW 1.5M
- MIRM 476.2K
- Earning Date
- OSW 04-30-2025
- MIRM 05-07-2025
- Dividend Yield
- OSW 0.71%
- MIRM N/A
- EPS Growth
- OSW N/A
- MIRM N/A
- EPS
- OSW 0.69
- MIRM N/A
- Revenue
- OSW $895,019,000.00
- MIRM $336,888,000.00
- Revenue This Year
- OSW $7.70
- MIRM $29.51
- Revenue Next Year
- OSW $8.41
- MIRM $20.27
- P/E Ratio
- OSW $24.55
- MIRM N/A
- Revenue Growth
- OSW 12.72
- MIRM 80.76
- 52 Week Low
- OSW $12.07
- MIRM $23.14
- 52 Week High
- OSW $23.01
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- OSW 48.17
- MIRM 34.64
- Support Level
- OSW $16.52
- MIRM $37.83
- Resistance Level
- OSW $17.97
- MIRM $40.32
- Average True Range (ATR)
- OSW 1.06
- MIRM 2.47
- MACD
- OSW 0.18
- MIRM -0.33
- Stochastic Oscillator
- OSW 72.61
- MIRM 25.14
About OSW OneSpaWorld Holdings Limited
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.